title: Antibody responses following induction of antigen-specific tolerance with antigen-coupled cells.
abstract: We have recently demonstrated the safety and tolerability of a novel therapeutic regimen employing autologous blood cells chemically coupled with seven myelin peptides to induce antigen-specific tolerance in MS (ETIMS study). The aim of the current study was an extended safety analysis to assess the effect of the ETIMS approach on antibodies to common autoantigens, the myelin peptides used and common recall antigens. None of the patients showed induction of autoantibody responses. One patient had a measurable myelin peptide-specific response at baseline, which was reduced after treatment. Total immunoglobulins and recall antibody responses showed no significant change.
authors.affiliation: Clinical Department of Neurology, Innsbruck Medical University, Austria.
authors.forename: Patrick
authors.initials: P
authors.lastname: Peschl
authors.affiliation: Clinical Department of Neurology, Innsbruck Medical University, Austria.
authors.forename: Markus
authors.initials: M
authors.lastname: Reindl
authors.affiliation: Clinical Department of Neurology, Innsbruck Medical University, Austria.
authors.forename: Kathrin
authors.initials: K
authors.lastname: Schanda
authors.affiliation: Neuroimmunology and Multiple Sclerosis Research, Department of Neurology, University Hospital Zurich, Switzerland.
authors.forename: Mireia
authors.initials: M
authors.lastname: Sospedra
authors.affiliation: Neuroimmunology and Multiple Sclerosis Research, Department of Neurology, University Hospital Zurich, Switzerland.
authors.forename: Roland
authors.initials: R
authors.lastname: Martin
authors.affiliation: Clinical Department of Neurology, Innsbruck Medical University, Austria/Neuroimmunology and Multiple Sclerosis Research, Department of Neurology, University Hospital Zurich, Switzerland andreas.lutterotti@i-med.ac.at.
authors.forename: Andreas
authors.initials: A
authors.lastname: Lutterotti
mesh_terms: D000328:Adult; D000917:Antibody Formation / Q000187:drug effects*; D001323:Autoantibodies / Q000032:analysis; D001324:Autoantigens / Q000009:adverse effects / Q000627:therapeutic use*; D001773:Blood Cells / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D007108:Immune Tolerance; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000628:therapy*; D063308:Myelin-Oligodendrocyte Glycoprotein / Q000276:immunology; D014612:Vaccines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D001323:Autoantibodies; D001324:Autoantigens; D007074:Immunoglobulin G; D063308:Myelin-Oligodendrocyte Glycoprotein; D014612:Vaccines
keywords: Multiple sclerosis; antibody; antigen-coupled cell; myelin; tolerance